Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745350 | 0.92 | PTGS2 (0.41) | PTGS2NR1H2NR1H3GRM2 | |
| SCHEMBL6744681 | 0.84 | PTGS2 (0.40) | PTGS2NR1H2NR1H3GRM2SCN9A | |
| SCHEMBL6743648 | 0.84 | PTGS2 (0.40) | PTGS2NR1H2NR1H3ALOX5APFEN1 | |
| SCHEMBL6746028 | 0.84 | PTGS2 (0.49) | PTGS2NR1H2NR1H3 | |
| SCHEMBL6745224 | 0.84 | NR1H2 (0.40) | PTGS2NR1H2NR1H3SCN9AALOX5AP | |
| SCHEMBL6747092 | 0.82 | KIF11 (0.33) | PTGS2GRM2 | |
| SCHEMBL6746854 | 0.82 | PTGS2 (0.49) | PTGS2NR1H2NR1H3 | |
| SCHEMBL6747448 | 0.82 | NR1H2 (0.37) | NR1H2NR1H3SCN9A | |
| SCHEMBL6743034 | 0.81 | NR1H2 (0.40) | PTGS2NR1H2NR1H3SCN9AALOX5AP | |
| SCHEMBL6747149 | 0.81 | PTGS2 (0.52) | PTGS2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | disclosed |